Stockscreener 앱 받기
4.27
4.26%
-0.19
시간 외 거래:
4.31
0.04
+0.94%
전일 마감가:
$4.46
열려 있는:
$4.29
하루 거래량:
3.75M
Relative Volume:
0.62
시가총액:
$1.16B
수익:
$8.10M
순이익/손실:
$-92.72M
주가수익비율:
-11.96
EPS:
-0.3571
순현금흐름:
$-82.52M
1주 성능:
-14.43%
1개월 성능:
-10.29%
6개월 성능:
+65.50%
1년 성능:
+218.66%
1일 변동 폭
$4.00
$4.54
1주일 범위
$3.97
$5.25
52주 변동 폭
$1.05
$5.5082
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
명칭
Taysha Gene Therapies Inc
전화
(214) 612-0000
주소
3000 PEGASUS PARK DRIVE, DALLAS
TSHA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.27 | 1.22B | 8.10M | -92.72M | -82.52M | -0.3571 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Raymond James | Strong Buy |
| 2025-07-11 | 개시 | BofA Securities | Buy |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-04-09 | 개시 | Piper Sandler | Overweight |
| 2023-02-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-03-09 | 개시 | Robert W. Baird | Outperform |
| 2022-03-01 | 개시 | Wells Fargo | Overweight |
| 2022-02-18 | 개시 | SMBC Nikko | Outperform |
| 2021-12-16 | 개시 | Guggenheim | Buy |
| 2021-07-16 | 개시 | Needham | Buy |
| 2021-06-24 | 개시 | Truist | Buy |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-06-09 | 개시 | Wedbush | Outperform |
| 2021-06-08 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-11 | 재개 | Jefferies | Buy |
| 2021-02-24 | 개시 | William Blair | Outperform |
| 2021-01-05 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-19 | 개시 | Goldman | Buy |
| 2020-10-19 | 개시 | Jefferies | Buy |
| 2020-10-19 | 개시 | Morgan Stanley | Overweight |
모두보기
Taysha Gene Therapies Inc 주식(TSHA)의 최신 뉴스
Taysha Gene Therapies Inc (TSHA) Q3 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Taysha Gene Therapies (TSHA) Advances with TSHA-102 Breakthrough Designation - GuruFocus
Taysha Gene Therapies Q3 2025 Earnings Call Transcript - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap DownHere's What Happened - MarketBeat
Taysha Gene Therapies (TSHA): Assessing Valuation Following Strong Share Price Gains - Yahoo Finance
Earnings call transcript: Taysha Gene Therapies Q3 2025 sees EPS in line with forecasts - Investing.com Philippines
Earnings Flash (TSHA) Taysha Gene Therapies Posts Q3 Net Loss $0.09 a Share - MarketScreener
Taysha (TSHA) Advances with FDA Breakthrough Designation and Key Clinical Milestones - GuruFocus
Taysha (TSHA) Financial Outlook: Cash Reserves to Support Operat - GuruFocus
Taysha Gene Therapies Amends Sales Agreement, Expands Offering - TipRanks
Taysha Gene Therapies Q3 net loss widens as R&D costs rise - MarketScreener
Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Taysha Gene (NASDAQ: TSHA) wins FDA Breakthrough Therapy for TSHA-102 in Rett syndrome - Stock Titan
Will Taysha Gene Therapies Inc. stock recover after recent dropWeekly Trade Analysis & Free Risk Controlled Daily Trade Plans - newser.com
How Taysha Gene Therapies Inc. stock benefits from strong dollarJuly 2025 News Drivers & Risk Adjusted Buy/Sell Alerts - newser.com
Short interest data insights for Taysha Gene Therapies Inc.Market Sentiment Review & Free Safe Entry Trade Signal Reports - newser.com
Can Taysha Gene Therapies Inc. hit a new high this monthWeekly Market Report & Capital Efficiency Focused Ideas - newser.com
Using Bollinger Bands to evaluate Taysha Gene Therapies Inc.Weekly Trade Review & Entry Point Confirmation Signals - newser.com
What To Expect From Taysha Gene Therapies Inc (TSHA) Q3 2025 Ear - GuruFocus
Can Taysha Gene Therapies Inc. stock sustain institutional interest2025 Investor Takeaways & Long-Term Growth Portfolio Plans - newser.com
What To Expect From Taysha Gene Therapies Inc (TSHA) Q3 2025 Earnings - Yahoo Finance
Is Taysha Gene Therapies Inc. stock near bottom after declineFed Meeting & Weekly High Potential Stock Alerts - newser.com
Why Taysha Gene Therapies Inc. stock is favored by top institutions2025 Key Lessons & Weekly Top Gainers Alerts - newser.com
Detecting support and resistance levels for Taysha Gene Therapies Inc.Rate Hike & Fast Entry Momentum Trade Alerts - newser.com
How institutional ownership impacts Taysha Gene Therapies Inc. stockJuly 2025 Review & Free Safe Capital Growth Stock Tips - newser.com
Will breakout in Taysha Gene Therapies Inc. lead to full recoveryMarket Movement Recap & Consistent Profit Trading Strategies - newser.com
Can momentum traders help lift Taysha Gene Therapies Inc.Quarterly Earnings Summary & Entry Point Confirmation Alerts - newser.com
Candlestick signals on Taysha Gene Therapies Inc. stock todayIPO Watch & Accurate Entry and Exit Point Alerts - newser.com
Why Taysha Gene Therapies Inc. stock is rated strong buyTrade Signal Summary & Weekly High Return Stock Forecasts - newser.com
Will a bounce in Taysha Gene Therapies Inc. offer an exitJuly 2025 PostEarnings & Weekly Market Pulse Alerts - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Taysha Gene Therapies (TSHA) Expected to Announce Earnings on Tuesday - MarketBeat
Taysha Gene Therapies’ REVEAL Adult Study: A New Hope for Rett Syndrome? - TipRanks
Taysha Gene Therapies Inc (TSHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Taysha Gene Therapies Inc 주식 (TSHA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D |
Sep 10 '25 |
Option Exercise |
0.70 |
41,150 |
28,760 |
1,206,439 |
| Nagendran Sukumar | President and Head of R&D |
Sep 10 '25 |
Sale |
3.23 |
200,000 |
646,000 |
1,006,439 |
1.45%
0.86%
자본화:
|
볼륨(24시간):